The drug is currently approved for treating heavily treatment-experienced (HTE) adults with multi-drug resistant HIV.

Stay up-to-date with the Dr. Reddy's Laboratories Stock Liveblog, your trusted source for real-time updates and thorough ...

Dr Reddy's Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with ...

Dr. Reddy’s and Hetero partner with Gilead Sciences to manufacture and distribute Lenacapavir for HIV treatment in LMICs.

Dr Reddy's Laboratories and Hetero sign non-exclusive, royalty-free agreements with Gilead Sciences to manufacture ...

Lenacapavir is a US Food and Drug Administration (FDA) approved medication indicated for the treatment of HIV type 1 (HIV-1) ...

Dr Reddy’s Laboratories said it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead ...

Hyderabad-based pharma giant Dr Reddy’s Ltd finalizes its largest acquisition by buying British Haleon Plc’s non-US nicotine ...

Shares of Dr. Reddy's Laboratories Ltd. 500124 inched up 0.74% to 6,743.20 Indian rupees Thursday, on what proved to be an ...

Dr Reddy’s Laboratories SA, Switzerland, an arm of Dr Reddy’s Laboratories, has completed the previously-announced ...

Welcome to the Dr. Reddy's Laboratories Stock Liveblog, your ultimate source for real-time updates and analysis of one of the ...

Dr. Nilay Reddy, 29, a Cornea and Anterior Segment Fellow at the LV Prasad Eye Hospital, was travelling to the airport from ...